284 related articles for article (PubMed ID: 23958375)
21. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Bergh J; Bondarenko IM; Lichinitser MR; Liljegren A; Greil R; Voytko NL; Makhson AN; Cortes J; Lortholary A; Bischoff J; Chan A; Delaloge S; Huang X; Kern KA; Giorgetti C
J Clin Oncol; 2012 Mar; 30(9):921-9. PubMed ID: 22331954
[TBL] [Abstract][Full Text] [Related]
22. Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
Komatsu Y; Ohki E; Ueno N; Yoshida A; Toyoshima Y; Ueda E; Houzawa H; Togo K; Nishida T
Jpn J Clin Oncol; 2015 Nov; 45(11):1016-22. PubMed ID: 26373318
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI
Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223
[TBL] [Abstract][Full Text] [Related]
24. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Lee J; Kim HH; Ro SM; Yang JH
PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
28. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
[TBL] [Abstract][Full Text] [Related]
29. Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Liao Y; Fan Y; Wan Y; Li J; Peng L
Chemotherapy; 2013; 59(3):207-13. PubMed ID: 24335152
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
31. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Han JY; Kim HY; Lim KY; Han JH; Lee YJ; Kwak MH; Kim HJ; Yun T; Kim HT; Lee JS
Lung Cancer; 2013 Feb; 79(2):137-42. PubMed ID: 23182663
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
35. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Geldart T; Chester J; Casbard A; Crabb S; Elliott T; Protheroe A; Huddart RA; Mead G; Barber J; Jones RJ; Smith J; Cowles R; Evans J; Griffiths G
Eur Urol; 2015 Apr; 67(4):599-602. PubMed ID: 25465968
[TBL] [Abstract][Full Text] [Related]
36. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
[TBL] [Abstract][Full Text] [Related]
38. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Chen Y; Guan Y; Wang J; Ma F; Luo Y; Chen S; Zhang P; Li Q; Cai R; Li Q; Mo H; Lan B; Chen X; Zhao W; Xu B; Fan Y
Int J Cancer; 2020 Dec; 147(12):3490-3499. PubMed ID: 32588429
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
40. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Seidman AD; Brufsky A; Ansari RH; Hart LL; Stein RS; Schwartzberg LS; Stewart JF; Russell CA; Chen SC; Fein LE; De La Cruz Vargas JA; Kim SB; Cavalheiro J; Zhao L; Gill JF; Obasaju CK; Orlando M; Tai DF
Ann Oncol; 2011 May; 22(5):1094-1101. PubMed ID: 21084429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]